Assembly Biosciences Retained Earnings (Accumulated Deficit) 2010-2024 | ASMB

Assembly Biosciences retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Assembly Biosciences Annual Retained Earnings (Accumulated Deficit)
(Millions of US $)
2023 $-786
2022 $-725
2021 $-631
2020 $-502
2019 $-439
2018 $-342
2017 $-251
2016 $-208
2015 $-164
2014 $-136
2013 $-112
2012 $-92
2011 $-68
2010 $-33
2009 $-18
Assembly Biosciences Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $)
2024-06-30 $-806
2024-03-31 $-795
2023-12-31 $-786
2023-09-30 $-775
2023-06-30 $-760
2023-03-31 $-743
2022-12-31 $-725
2022-09-30 $-702
2022-06-30 $-679
2022-03-31 $-655
2021-12-31 $-631
2021-09-30 $-571
2021-06-30 $-552
2021-03-31 $-529
2020-12-31 $-502
2020-09-30 $-462
2020-06-30 $-459
2020-03-31 $-466
2019-12-31 $-439
2019-09-30 $-412
2019-06-30 $-387
2019-03-31 $-369
2018-12-31 $-342
2018-09-30 $-316
2018-06-30 $-294
2018-03-31 $-267
2017-12-31 $-251
2017-09-30 $-248
2017-06-30 $-236
2017-03-31 $-222
2016-12-31 $-208
2016-09-30 $-197
2016-06-30 $-185
2016-03-31 $-175
2015-12-31 $-164
2015-09-30 $-156
2015-06-30 $-150
2015-03-31 $-143
2014-12-31 $-136
2014-09-30 $-129
2014-06-30 $-118
2014-03-31 $-116
2013-12-31 $-112
2013-09-30 $-106
2013-06-30 $-101
2013-03-31 $-96
2012-12-31 $-92
2012-09-30 $-89
2012-06-30 $-83
2012-03-31 $-76
2011-12-31 $-68
2011-09-30 $-49
2011-06-30 $-43
2011-03-31 $-36
2010-12-31 $-33
2010-09-30
2010-06-30
2010-03-31
2009-12-31 $-18
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.105B $0.007B
Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.384B 6.36
Dr Reddy's Laboratories (RDY) India $12.329B 23.59
BridgeBio Pharma (BBIO) United States $4.629B 0.00
Bausch Health Cos (BHC) Canada $3.358B 2.43
Amphastar Pharmaceuticals (AMPH) United States $2.294B 13.79
Supernus Pharmaceuticals (SUPN) United States $2.089B 28.44
Taysha Gene Therapies (TSHA) United States $0.490B 79.67
Personalis (PSNL) United States $0.278B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00